112 related articles for article (PubMed ID: 17027836)
1. Hypertension, diuretics, and uric acid.
Reyes AJ; Leary WP
Am J Hypertens; 2006 Oct; 19(10):1093-4. PubMed ID: 17027836
[No Abstract] [Full Text] [Related]
2. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
[TBL] [Abstract][Full Text] [Related]
3. [Organ protection by angiotensin II receptor blockers].
Kumagai H; Onami T; Takimoto C; Iigaya K; Saruta T
Nihon Rinsho; 2004 Mar; 62 Suppl 3():569-73. PubMed ID: 15171437
[No Abstract] [Full Text] [Related]
4. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout.
Liberopoulos E; Christides D; Elisaf M
J Hypertens; 2002 Feb; 20(2):347. PubMed ID: 11821722
[No Abstract] [Full Text] [Related]
5. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
[TBL] [Abstract][Full Text] [Related]
6. Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
Kim S
Curr Med Res Opin; 2003; 19(5):442-4. PubMed ID: 13678484
[TBL] [Abstract][Full Text] [Related]
7. New angiotensin-II blocker.
Lilley LL; Guanci R
Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540
[No Abstract] [Full Text] [Related]
8. [GOUT AND HYPERTENSION].
Belovol AN; Knyazkova II; Miroshnykova IA
Lik Sprava; 2015; (1-2):32-8. PubMed ID: 26118024
[TBL] [Abstract][Full Text] [Related]
9. Effects of losartan/hydrochlorothiazide on serum uric acid levels and blood pressure in hypertensive patients.
Fujimori S; Oka Y; Ogata N; Eto K
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1030-4. PubMed ID: 22132952
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and effect on plasma B-type natriuretic peptide concentration of losartan-hydrochlorothiazide for hypertension uncontrolled by losartan-based therapy: subanalysis of a Multicentre Prospective Observational Study.
Meno H; Inou T; Tanaka M; Tsuchiya Y; Shiga Y; Kobayashi K; Nakamura Y; Ota T; Kubara I
Arzneimittelforschung; 2012 Sep; 62(9):414-9. PubMed ID: 22773432
[TBL] [Abstract][Full Text] [Related]
11. [AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
MMW Fortschr Med; 2003 Apr; 145(15):62. PubMed ID: 15104271
[No Abstract] [Full Text] [Related]
12. [The pleiotropic effects of losartan--the importance of decreasing uric acid level].
Csiky B; Markó L; Mohás M; Cseh J; Mikolás E; Szíjártó I; Wittmann I
Lege Artis Med; 2008 Oct; 18(10):663-6. PubMed ID: 19227608
[TBL] [Abstract][Full Text] [Related]
13. [Serum uric acid prevalence and changes post various antihypertensive agents in patients with essential hypertension].
Chen H; Yang LQ; Yu L; Wu XY; Lu LH; Gui W
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jun; 36(6):523-6. PubMed ID: 19100066
[TBL] [Abstract][Full Text] [Related]
14. Is uric acid really an independent cardiovascular risk factor?
Beevers DG; Lip GY
Lancet; 1998 Nov; 352(9139):1556. PubMed ID: 9820335
[No Abstract] [Full Text] [Related]
15. [Protective vascular effect of angiotensin receptor blocker (ARB)].
Yamakado M
Nihon Rinsho; 2002 Oct; 60(10):2020-7. PubMed ID: 12397701
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
Andersson OK; Neldam S
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
[No Abstract] [Full Text] [Related]
17. [Experiences with a new salureticum in essential hypertension].
Hammer O; Dembowski U
Med Klin; 1969 Oct; 64(41):1862-4. PubMed ID: 5397042
[No Abstract] [Full Text] [Related]
18. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
Schiffrin EL; Touyz RM
J Am Coll Cardiol; 2003 Sep; 42(5):911-3. PubMed ID: 12957442
[No Abstract] [Full Text] [Related]
19. Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus?
Doggrell SA
Curr Opin Investig Drugs; 2005 Mar; 6(3):242-4. PubMed ID: 15816499
[No Abstract] [Full Text] [Related]
20. [The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Ohashi H; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():297-301. PubMed ID: 15999723
[No Abstract] [Full Text] [Related]
[Next] [New Search]
